



SAFETY DATA SHEET

Revision date: 22-Oct-2018

Version: 2.1

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Methimazole Tablets

Trade Name: TAPAZOLE
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for Hyperthyroidism

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A

Label Elements

Signal Word: Danger
Hazard Statements: H360D - May damage the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up



SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 2 of 9
Version: 2.1

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Methimazole	60-56-0	200-482-4	Repr.1A (H360D)	5-10
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 3 of 9
Version: 2.1

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product used for Hyperthyroidism

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Starch, pregelatinized

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 4 of 9
Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Magnesium stearate	
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Talc (non-asbestiform)	
ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm ³
	6.0 mg/m ³
	3.0 mg/m ³
Czech Republic OEL - TWA	2.0 mg/m ³
Denmark OEL - TWA	0.3 fiber/cm ³
Finland OEL - TWA	0.5 fiber/cm ³
Greece OEL - TWA	10 mg/m ³
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³
Lithuania OEL - TWA	2 mg/m ³
	1 mg/m ³
Netherlands OEL - TWA	0.25 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Romania OEL - TWA	2 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³
Corn Starch	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 5 of 9
Version: 2.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Ireland OEL - TWAs	10 mg/m ³ 4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Methimazole

Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	Color:	White to off-white
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
Lactose NF, monohydrate			

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 6 of 9
Version: 2.1

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Talc (non-asbestiform)

No data available

Magnesium stearate

No data available

Starch, pregelatinized

No data available

Corn Starch

No data available

Methimazole

Predicted 7.4 Log D -2.743

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Known Clinical Effects: This compound can cross the placenta in pregnant women. Can induce cretinism and goiter in the developing fetus. Adverse effects associated with therapeutic use include decrease in platelets and red/white blood cells (pancytopenia), decreased white blood cells (leukopenia), thrombocytopenia, inflammation of the liver (hepatitis), changes in liver function, effects on the thyroid, headache, skin rash, hives, redness and swelling of the skin (urticaria), loss of hair, nausea, vomiting, loss of taste.

Acute Toxicity: (Species, Route, End Point, Dose)

Talc (non-asbestiform)

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 7 of 9
Version: 2.1

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 > 1600 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m³

Methimazole

Rat Oral LD50 2250 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Methimazole

Embryo / Fetal Development Rat Oral 50 mg/kg/day LOAEL Developmental toxicity

Embryo / Fetal Development Rabbit No route specified Dose not specified Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Methimazole

In Vitro Chromosome Aberration Positive

In Vivo Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Methimazole

2 Year(s) Rat Oral 0.5 mg/kg/day NOAEL Thyroid, Tumors

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Talc (non-asbestiform)

IARC:

Group 3 (Not Classifiable)

Methimazole

IARC:

Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:

No data available

Persistence and Degradability:

No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Methimazole

Predicted 7.4 Log D -2.743

Mobility in Soil:

No data available

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 8 of 9
Version: 2.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Methimazole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	developmental toxicity 7/1/1990
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-482-4

Starch, pregelatinized

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Methimazole Tablets
Revision date: 22-Oct-2018

Page 9 of 9
Version: 2.1

15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
Talc (non-asbestiform)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9
Corn Starch	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6
Lactose NF, monohydrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360D - May damage the unborn child

Data Sources:	Publicly available toxicity information. Pfizer proprietary drug development information.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date:	22-Oct-2018 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet